Natalizumab as a disease-modifying therapy in chronic inflammatory demyelinating polyneuropathy - A report of three cases

European Neurology

Volumn 73, Issue 5-6, 2015, Pages 294-302

  Vallat, Jean Michel ^a   Mathis, Stéphane ^b   Ghorab, Karima ^a   Milor, Michel André ^a   Richard, Laurence ^a   Magy, Laurent ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Blood nerve barrier; CIDP; Immune mediated neuropathy; Natalizumab; VCAM1; VLA4

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; NATALIZUMAB; PREDNISOLONE; IMMUNOLOGIC FACTOR;

ADULT; AGED; ARTICLE; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DRUG EFFICACY; FEMALE; HUMAN; NERVE CONDUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

ADULT; AGED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NATALIZUMAB; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84928747930     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000381767     Document Type: Article

References (29)

1. Vallat JM, Sommer C, Magy L: Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402-412.
2. Joint Task Force of the EFNS and the PNS: European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society - first revision. J Peripher Nerv Syst 2010; 15: 1-9.
3. Querol L, Rojas-Garcia R, Casasnovas C, et al: Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. Muscle Nerve 2013; 48: 870-876.
4. Dalakas MC, Engel WK: Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 1980; 37: 637-640.
5. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al: Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013; 73: 370-380.
6. Odaka M, Tatsumoto M, Susuki K, Hirata K, Yuki N: Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry 2005; 76: 1115-1120.
7. Brannagan TH 3rd, Pradhan A, Heiman-Patterson T, et al: High-dose cyclophosphamide without stem-cell rescue for refractory cidp. Neurology 2002; 58: 1856-1858.
8. Cocito D, Grimaldi S, Paolasso I, et al: Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol 2011; 18: 1417-1421.
9. RMC Trial Group: Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8: 158-164.
10. Dyck PJ, O'Brien P, Swanson C, Low P, Daube J: Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35: 1173-1176.
11. Mahdi-Rogers M, Swan AV, van Doorn PA, Hughes RA: Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2010; 11: CD003280.
12. Magy L, Mathis S, Vallat JM: Diagnostic and therapeutic challenges in chronic inflammatory demyelinating polyneuropathy and other immune-mediated neuropathies. Curr Opin Crit Care 2011; 17: 101-105.
13. Dalakas MC: Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. J Peripher Nerv Syst 2012; 17: 34-39.
14. Wolf C, Menge T, Stenner MP, et al: Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2010; 67: 881-883.
15. Graham RC, Hughes RA: A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 2006; 77: 973-976.
16. Vallat JM, Tabaraud F, Magy L, et al: Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve 2003; 27: 478-485.
17. Van den Bergh PY, Hadden RD, Bouche P, et al: European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society - first revision. Eur J Neurol 2010; 17: 356-363.
18. Hughes RA, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; 1:CD003280.
19. Shimizu F, Omoto M, Sano Y, et al: Sera from patients with multifocal motor neuropathy disrupt the blood-nerve barrier. J Neurol Neurosurg Psychiatry 2014; 85: 526-537.
20. Kanda T: Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies. J Neurol Neurosurg Psychiatry 2013; 84: 208-212.
21. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
22. O'Connor P: Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther 2007; 7: 123-136.
23. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N: Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
24. Leussink VI, Zettl UK, Jander S, et al: Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol 2002; 103: 131-136.
25. Enders U, Lobb R, Pepinsky RB, Hartung HP, Toyka KV, Gold R: The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat. Brain 1998; 121: 1257-1266.
26. Fox RJ, Cree BA, De Soze J, et al: MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 2014; 82: 1491-1498.
27. Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T: Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 2006; 77: 66-70.
28. Delbue S, Elia F, Carloni C, et al: JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. J Neurovirol 2014, Epub ahead of print.
29. Van Assche G, Van Ranst M, Sciot R, et al: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-368.